Phase 3 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by a tissue or cell sample.
• People whose cancer has spread to a limited number of places in the body — between one and five separate areas outside the pancreas (called oligometastatic disease), as measured on recent scans.
• People who are well enough to carry out basic daily activities, as assessed using a standard health scale (a score of 2 or lower on the ECOG scale, where 0 means fully active and 2 means able to care for oneself but unable to do work activities).
• People whose cancer in all affected areas — including any spread — may be treated with a combination of local treatments such as radiation therapy, surgery, ablation, or embolization.
• People who have had recent imaging (within 4 weeks before joining the study), including a PET/CT scan or CT scan of the chest, abdomen, and pelvis (an MRI may be used instead where appropriate).
• People who have normal enough organ function, confirmed by blood tests done within 4 weeks before joining the study.
• Women who could become pregnant must not be breastfeeding, must have a negative pregnancy test, and must agree to use approved contraception from the start of the study until 3 months after stopping the study treatment.
• Men who are sexually active with a partner who could become pregnant must agree to use approved contraception for the duration of the study and for 6 months after the last dose of study treatment.
• People who previously had more than five areas of cancer spread but whose cancer responded to treatment and has been reduced to five or fewer areas for at least 6 months may be considered eligible, at the principal investigator's discretion.
• People who need urgent treatment to the brain or other painful areas before joining the study may still be considered eligible, though those treated areas will count toward the total number of affected sites (confirm with trial site).

Who may not be able to join:

• People who have fluid build-up caused by cancer spreading to areas such as around the lungs (pleural effusion) or abdomen (ascites) — though people with a very small effusion that cannot be sampled may still be considered eligible (confirm with trial site).
• People whose cancer has spread to the membranes surrounding the brain or spinal cord (leptomeningeal disease).
• People whose cancer has spread across the lining of the abdomen (peritoneal carcinomatosis).
• People who are not able to understand and agree to participate in the study due to cognitive difficulties.
• People with any condition that, in the investigator's opinion, could interfere with treatment or make the study results hard to interpret.
• People whose cancer has spread widely throughout the bone marrow in areas where it cannot be seen on scans.
• People who have already received more than four separate courses of systemic (whole-body) treatment for their metastatic cancer.
• People with active scleroderma, lupus, or certain other rheumatological (joint and immune system) diseases that may make radiation therapy unsafe — though these individuals may still be considered eligible if they can receive non-radiation local treatments instead (confirm with trial site).
• People with a known psychiatric condition or substance use disorder that would prevent them from fully taking part in the trial.
• People who have another separate active cancer that, in the treating doctors' opinion, poses a significant risk to life alongside the pancreatic cancer being treated in this trial.

Important: Always verify eligibility with the trial site directly before applying.